RxDoctor Payments Data

Shanti Singh, MD

Internal Medicine · Kissimmee, FLNPI 1144291980

Payments from drug & device makers

$5,873in general payments, 2019–2025

Across 315 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$925
  • Novo Nordisk$604
  • Lilly USA, LLC$443
  • Boehringer Ingelheim$441
  • Bayer$394
  • plus $2K from 12 others

What the payments were for

  • Food & beverage$5,860100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,873 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$55,919
Medicare patients
190
Services billed
667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol36$44,627
XareltoRivaroxaban31$43,559
JanuviaSitagliptin Phosphate24$37,950
Soliqua 100-33Insulin Glargine/Lixisenatide25$33,536
OzempicSemaglutide13$29,367
EliquisApixaban33$23,238
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$19,308
JardianceEmpagliflozin14$18,590
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$5,788
Rosuvastatin Calcium175$4,055
SynthroidLevothyroxine Sodium29$2,190
Atorvastatin Calcium217$2,161
Losartan Potassium161$1,730
Ezetimibe40$1,508
Venlafaxine Hcl ErVenlafaxine Hcl24$1,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,174$44,62736 claims
Johnson & JohnsonXarelto$136$43,55931 claims
MerckJanuvia$175$37,95024 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$347$33,53625 claims
Novo NordiskOzempic$604$29,36713 claims
PfizerEliquis$239$23,23833 claims
GSKTrelegy Ellipta$925$19,30814 claims
Boehringer IngelheimJardiance$441$18,59014 claims
AbbVieSynthroid$316$2,19029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →